(Q28200251)

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Conjugative transfer genes in staphylococcal isolates from the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989-1995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Changing Patterns of Resistance of Certain Common Pathogenic Bacteria to Antimicrobial Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Guidelines for the control of methicillin-resistant Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

The positive predictive value of isolating coagulase-negative staphylococci from blood cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

“Celbenin” - resistant Staphylococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Staphylococcus aureus and vancomycin: the sequel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Tolerance of Staphylococcus epidermidis grown from indwelling vascular catheters to antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

EXTRACTION OF A HIGHLY POTENT PENICILLIN INACTIVATOR FROM PENICILLIN RESISTANT STAPHYLOCOCCI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Antimicrobial Resistance in Hospital Organisms and Its Relation to Antibiotic Use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Activity of glycopeptides in combination with amikacin or rifampin against Staphylococcus epidermidis biofilms on plastic catheters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Staphylococcus epidermidis: emerging resistance and need for alternative agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Antibiotics and prevention of microbial colonization of catheters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Methicillin-resistant Staphylococcus aureus (MRSA) in the community: who's watching?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Coagulase-negative staphylococci: pathogens associated with medical progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

The in-vitro activity of linezolid (U-100766) and tentative breakpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Major trends in the microbial etiology of nosocomial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

European survey of glycopeptide susceptibility in Staphylococcus spp.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992-1993). The Alexander Project Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Decreased antimicrobial resistance after changes in antibiotic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Methicillin-resistant Staphylococcus aureus in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Development of new antibiotic resistance in methicillin-resistant but not methicillin-susceptible Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Vancomycin-resistant Staphylococcus aureus: infection control considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

The comparative efficacy and safety of teicoplanin and vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Current perspectives on glycopeptide resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970302-3